Literature DB >> 22961898

Increased resistance to multiple antimicrobials and altered resistance gene expression in CMY-2-positive Salmonella enterica following a simulated patient treatment with ceftriaxone.

Russell D Hamilton1, Holly J Hulsebus, Samina Akbar, Jeffrey T Gray.   

Abstract

Salmonellosis is one of the most common causes of food-borne disease in the United States. Increasing antimicrobial resistance and corresponding increases in virulence present serious challenges. Currently, empirical therapy for invasive Salmonella enterica infection includes either ceftriaxone or ciprofloxacin (E. L. Hohmann, Clin. Infect. Dis. 32:263-269, 2001). The bla(CMY-2) gene confers resistance to ceftriaxone, the antimicrobial of choice for pediatric patients with invasive Salmonella enterica infections, making these infections especially dangerous (J. M. Whichard et al., Emerg. Infect. Dis. 11:1464-1466, 2005). We hypothesized that bla(CMY-2)-positive Salmonella enterica would exhibit increased MICs to multiple antimicrobial agents and increased resistance gene expression following exposure to ceftriaxone using a protocol that simulated a patient treatment in vitro. Seven Salmonella enterica strains survived a simulated patient treatment in vitro and, following treatment, exhibited a significantly increased ceftriaxone MIC. Not only would these isolates be less responsive to further ceftriaxone treatment, but because the bla(CMY-2) genes are commonly located on large, multidrug-resistant plasmids, increased expression of the bla(CMY-2) gene may be associated with increased expression of other drug resistance genes located on the plasmid (N. D. Hanson and C. C. Sanders, Curr. Pharm. Des. 5:881-894, 1999). The results of this study demonstrate that a simulated patient treatment with ceftriaxone can alter the expression of antimicrobial resistance genes, including bla(CMY-2) and floR in S. enterica serovar Typhimurium and S. enterica serovar Newport. Additionally, we have shown increased MICs following a simulated patient treatment with ceftriaxone for tetracycline, amikacin, ceftriaxone, and cefepime, all of which have resistance genes commonly located on CMY-2 plasmids. The increases in resistance observed are significant and may have a negative impact on both public health and antimicrobial resistance of Salmonella enterica.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961898      PMCID: PMC3485971          DOI: 10.1128/AEM.02077-12

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  21 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria.

Authors:  C Jacobs; J M Frère; S Normark
Journal:  Cell       Date:  1997-03-21       Impact factor: 41.582

Review 3.  Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae.

Authors:  N D Hanson; C C Sanders
Journal:  Curr Pharm Des       Date:  1999-11       Impact factor: 3.116

4.  Pharmacokinetics of ceftriaxone in pediatric patients with meningitis.

Authors:  R W Steele; L B Eyre; R W Bradsher; R E Weinfeld; I H Patel; J Spicehandler
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

5.  Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase.

Authors:  E F Dunne; P D Fey; P Kludt; R Reporter; F Mostashari; P Shillam; J Wicklund; C Miller; B Holland; K Stamey; T J Barrett; J K Rasheed; F C Tenover; E M Ribot; F J Angulo
Journal:  JAMA       Date:  2000-12-27       Impact factor: 56.272

Review 6.  Nontyphoidal salmonellosis.

Authors:  E L Hohmann
Journal:  Clin Infect Dis       Date:  2001-01-15       Impact factor: 9.079

7.  Characterization and localization of drug resistance determinants in multidrug-resistant, integron-carrying Salmonella enterica serotype Typhimurium strains.

Authors:  B Guerra; E Junker; A Miko; R Helmuth; M C Mendoza
Journal:  Microb Drug Resist       Date:  2004       Impact factor: 3.431

8.  FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States.

Authors:  Andrew C Voetsch; Thomas J Van Gilder; Frederick J Angulo; Monica M Farley; Sue Shallow; Ruthanne Marcus; Paul R Cieslak; Valerie C Deneen; Robert V Tauxe
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

9.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

10.  Foodborne illness acquired in the United States--major pathogens.

Authors:  Elaine Scallan; Robert M Hoekstra; Frederick J Angulo; Robert V Tauxe; Marc-Alain Widdowson; Sharon L Roy; Jeffery L Jones; Patricia M Griffin
Journal:  Emerg Infect Dis       Date:  2011-01       Impact factor: 6.883

View more
  2 in total

Review 1.  Antibiotics in Canadian poultry productions and anticipated alternatives.

Authors:  Moussa S Diarra; François Malouin
Journal:  Front Microbiol       Date:  2014-06-17       Impact factor: 5.640

2.  Population dynamics of enteric Salmonella in response to antimicrobial use in beef feedlot cattle.

Authors:  Naomi Ohta; Keri N Norman; Bo Norby; Sara D Lawhon; Javier Vinasco; Henk den Bakker; Guy H Loneragan; H Morgan Scott
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.